<?xml version="1.0" ?><!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st June 2018//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_180601.dtd"><PubmedArticleSet><PubmedArticle>    <MedlineCitation Status="In-Data-Review" Owner="NLM">        <PMID Version="1">30368240</PMID>        <DateRevised>            <Year>2018</Year>            <Month>11</Month>            <Day>14</Day>        </DateRevised>        <Article PubModel="Electronic">            <Journal>                <ISSN IssnType="Electronic">1742-6405</ISSN>                <JournalIssue CitedMedium="Internet">                    <Volume>15</Volume>                    <Issue>1</Issue>                    <PubDate>                        <Year>2018</Year>                        <Month>Oct</Month>                        <Day>27</Day>                    </PubDate>                </JournalIssue>                <Title>AIDS research and therapy</Title>                <ISOAbbreviation>AIDS Res Ther</ISOAbbreviation>            </Journal>            <ArticleTitle>Non-AIDS defining cancer (NADC) among HIV-infected patients at an oncology tertiary-care center in Mexico.</ArticleTitle>            <Pagination>                <MedlinePgn>16</MedlinePgn>            </Pagination>            <ELocationID EIdType="doi" ValidYN="Y">10.1186/s12981-018-0202-2</ELocationID>            <Abstract>                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Non-AIDS defining cancers (NADCs) have been an increasing cause of morbidity and mortality in patients with HIV. There is no data on the spectrum of NADCs in Mexico. We describe the type of neoplasms, clinical characteristics, and outcomes of HIV-infected patients with NADCs.</AbstractText>                <AbstractText Label="METHODS" NlmCategory="METHODS">We conducted a retrospective study of all patients with confirmed diagnosis of NADC attending the HIV/AIDS clinic at the National Cancer Institute in Mexico City (a tertiary-care center for adult patients with cancer) from January 1990 to December 2016.</AbstractText>                <AbstractText Label="RESULTS" NlmCategory="RESULTS">From 1126 HIV-positive individuals seen at the institute since 1990, 127 (11.3%) were diagnosed with NADCs; seven patients developed two NADCs during their follow-up. At diagnosis of NADC median age was 43.7 ± 10.9 years; 101 (79.5%) were male; median CD4 was 273 cells/mm<sup>3</sup>, 70 patients had a CD4 count of &gt; 200 cells/mm<sup>3</sup>, 73 had undetectable HIV viral load and 82 had taken combined antiretroviral therapy (cART) for more than 1 year. The most frequent NADCs were in men, Hodgkin lymphoma (34.3%) followed by anal cancer (15.7%), whereas in women, were vulvo-vaginal cancers associated to human papilloma virus (HPV) (51.8%), followed by breast cancer (25.9%). The main risk factor associated with death was cancer progression or relapse (OR, 28.2, 2.5-317.1; p = 0.007).</AbstractText>                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">HL- and HPV-related neoplasms are the commonest NADC in a cancer referral hospital from a middle-income country with universal access to cART since year 2005. Screening for early anogenital lesions should be emphasized in patients with HIV. It is essential to establish multidisciplinary groups involving Hemato-oncologists, Oncologists, Gynecologists, and HIV Specialists in the treatment of these patients.</AbstractText>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Cornejo-Juárez</LastName>                    <ForeName>P</ForeName>                    <Initials>P</Initials>                    <Identifier Source="ORCID">http://orcid.org/0000-0001-6331-8372</Identifier>                    <AffiliationInfo>                        <Affiliation>Infectious Diseases Department, Instituto Nacional de Cancerología (INCan), Av. San Fernando No. 22 Col. Sección XVI, Del. Tlalpan, 14000, Mexico City, CDMX, Mexico. patcornejo@yahoo.com.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Cavildo-Jerónimo</LastName>                    <ForeName>D</ForeName>                    <Initials>D</Initials>                    <AffiliationInfo>                        <Affiliation>Infectious Diseases Department, Instituto Nacional de Cancerología (INCan), Av. San Fernando No. 22 Col. Sección XVI, Del. Tlalpan, 14000, Mexico City, CDMX, Mexico.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Volkow-Fernández</LastName>                    <ForeName>P</ForeName>                    <Initials>P</Initials>                    <AffiliationInfo>                        <Affiliation>Infectious Diseases Department, Instituto Nacional de Cancerología (INCan), Av. San Fernando No. 22 Col. Sección XVI, Del. Tlalpan, 14000, Mexico City, CDMX, Mexico.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2018</Year>                <Month>10</Month>                <Day>27</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>England</Country>            <MedlineTA>AIDS Res Ther</MedlineTA>            <NlmUniqueID>101237921</NlmUniqueID>            <ISSNLinking>1742-6405</ISSNLinking>        </MedlineJournalInfo>        <CommentsCorrectionsList>            <CommentsCorrections RefType="Cites">                <RefSource>Oncology. 2011;80(1-2):42-9</RefSource>                <PMID Version="1">21606663</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Int J STD AIDS. 2017 Oct;28(12):1190-1198</RefSource>                <PMID Version="1">28178892</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Salud Publica Mex. 2011;53 Suppl 1:S37-45</RefSource>                <PMID Version="1">21877071</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Cancer. 2005 Oct 1;104(7):1505-11</RefSource>                <PMID Version="1">16104038</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Oncol Res Treat. 2017;40(3):106-112</RefSource>                <PMID Version="1">28253510</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Clin Oncol. 2009 Feb 20;27(6):884-90</RefSource>                <PMID Version="1">19114688</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Epidemiol Prev. 2015 Jul-Aug;39(4 Suppl 1):14-20</RefSource>                <PMID Version="1">26499410</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Acquir Immune Defic Syndr. 2011 Apr 15;56(5):467-73</RefSource>                <PMID Version="1">21239992</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>AIDS Res Hum Retroviruses. 2013 Jun;29(6):887-91</RefSource>                <PMID Version="1">23351216</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Br J Cancer. 2010 Jul 27;103(3):416-22</RefSource>                <PMID Version="1">20588274</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>BMC Cancer. 2015 Jun 23;15:478</RefSource>                <PMID Version="1">26100400</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Natl Cancer Inst. 2009 Aug 19;101(16):1120-30</RefSource>                <PMID Version="1">19648510</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Ann Intern Med. 2010 Oct 5;153(7):452-60</RefSource>                <PMID Version="1">20921544</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Curr Infect Dis Rep. 2010 Jan;12(1):46-55</RefSource>                <PMID Version="1">21308498</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Gynecol Oncol. 2001 Jul;82(1):27-31</RefSource>                <PMID Version="1">11426958</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>BMC Cancer. 2015 Mar 16;15:133</RefSource>                <PMID Version="1">25885746</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Eur J Intern Med. 2002 Jun;13(4):227-232</RefSource>                <PMID Version="1">12067817</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Clin Infect Dis. 2012 Nov;55(9):1228-35</RefSource>                <PMID Version="1">22776851</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>World J Virol. 2015 Aug 12;4(3):209-18</RefSource>                <PMID Version="1">26279983</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Acquir Immune Defic Syndr. 2015 Apr 15;68 Suppl 3:S274-85</RefSource>                <PMID Version="1">25768867</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>AIDS. 2016 Jul 17;30(11):1795-806</RefSource>                <PMID Version="1">27064994</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Natl Cancer Inst. 2011 May 4;103(9):753-62</RefSource>                <PMID Version="1">21483021</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Ann Oncol. 2016 Mar;27(3):397-408</RefSource>                <PMID Version="1">26681686</PMID>            </CommentsCorrections>        </CommentsCorrectionsList>        <KeywordList Owner="NOTNLM">            <Keyword MajorTopicYN="N">HIV</Keyword>            <Keyword MajorTopicYN="N">HPV</Keyword>            <Keyword MajorTopicYN="N">Mortality</Keyword>            <Keyword MajorTopicYN="N">Non-AIDS defining cancer</Keyword>        </KeywordList>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="received">                <Year>2018</Year>                <Month>06</Month>                <Day>25</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="accepted">                <Year>2018</Year>                <Month>10</Month>                <Day>10</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>10</Month>                <Day>29</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>10</Month>                <Day>29</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>10</Month>                <Day>29</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>epublish</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30368240</ArticleId>            <ArticleId IdType="doi">10.1186/s12981-018-0202-2</ArticleId>            <ArticleId IdType="pii">10.1186/s12981-018-0202-2</ArticleId>            <ArticleId IdType="pmc">PMC6204055</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle></PubmedArticleSet>